Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3058% above fair value
$0.99−0.12 (-10.78%)
Close on Nov 12, 2026Market cap $250.45MP/E –Yield –
Lineage Cell Therapeutics statistics
77 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Q3 FY2026, expected soon
- Last ex-dividend date
- Dec 15, 2003
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 10.14
- 2.29
Enterprise valuationIndustry
- EV / Sales
- 18.84
- 2.60
Share statisticsIndustry
- Shares Change (YoY)
- 10.3%
- 10.9%
- Shares Change (QoQ)
- 0.00%
- 0.51%
- Float
- 65M
- 49M
- Shares Held by Insiders
- 74.4%
- 12.1%
- Shares Held by Institutions
- 46.1%
- 56.4%
Short sellingIndustry
- Short Interest
- 24M
- –
- Short Interest Change
- -6.09%
- -0.76%
- Short % of Float
- 37.7%
- 9.04%
- Short % of Shares Outstanding
- 9.63%
- 6.30%
- Days to Cover
- 19.27
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $1.99
- –
- 52-Week Low
- $0.88
- –
- 20-Day Moving Average
- $1.01
- –
- 50-Day Moving Average
- $1.00
- –
- 200-Day Moving Average
- $1.30
- –
- Average True Range (14)
- $0.07
- –
- Price Change (1 Week)
- 0.73%
- 1.51%
- Price Change (1 Month)
- 7.93%
- -2.35%
- Price Change (3 Months)
- -7.45%
- -21.1%
- Price Change (6 Months)
- -24.4%
- -22.6%
- Price Change (YTD)
- -40.7%
- -22.6%
- Price Change (1 Year)
- -45.6%
- -20.7%
- Price Change (3 Years)
- 2.24%
- -27.4%
- Price Change (5 Years)
- -60.9%
- -77.3%
- Price Change (10 Years)
- -72.5%
- -62.7%
- Average Volume (10 Days)
- 1M
- –
- Average Volume (20 Days)
- 1M
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 1.13
- 0.79
- Relative Strength Index (14)
- 47.7
- 44.7
- Volatility (1 Year)
- 56.2%
- 80.4%
- Beta (5 Years)
- 0.97
- 1.07
MarginsIndustry
- EBITDA Margin
- -273.3%
- -27.7%
- FCF Margin
- -244.1%
- -9.20%
Returns on capitalIndustry
- Return on Equity (ROE)
- 3.93%
- -51.2%
- Return on Assets (ROA)
- 1.85%
- -40.6%
- Return on Invested Capital (ROIC)
- -1394.9%
- -32.9%
- Return on Capital Employed (ROCE)
- -33.0%
- -38.0%
Financial positionIndustry
- Current Ratio
- 5.96
- 3.30
- Quick Ratio
- 5.80
- 2.42
GrowthIndustry
- Revenue Growth (YoY)
- 0.18%
- 7.01%
- Revenue Growth (3Y CAGR)
- -0.33%
- 2.25%
- Revenue Growth (5Y CAGR)
- 51.5%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.11
- 0.40
- Revenue Per Employee
- $140.73K
- $429.29K
- Profits Per Employee
- $22.77K
- -$683.67K
- Employee Count
- 77
- 75
- WACC
- 9.82%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $45.18M
- $17.46M
- Net Cash Per Share
- $0.18
- $0.72
- Equity (Book Value)
- $67.06M
- $53.27M
- Book Value Per Share
- $0.27
- $1.50
- Tangible Book Value
- $24.69M
- $26.82M
- Working Capital
- $39.76M
- $79.47M
Cash flow (TTM)Industry
- Capital Expenditures
- -$636.00K
- -$944.00K
- FCF Per Share
- -$0.10
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- 0.70%
- -20.8%
- FCF Yield
- -10.6%
- -9.58%
Scores and fair valueIndustry
- Altman Z-Score
- -2.54
- 0.30
- Piotroski F-Score
- 4
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LCTX | S&P 500 | Difference | LCTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.8% | -2.7% | +6.5 pts | ||
| 3 months | -10.0% | -1.7% | −8.2 pts | ||
| Year to date | -40.7% | +11.9% | −52.6 pts | ||
| 1 year | -48.7% | +12.0% | −60.7 pts | ||
| 3 years | -4.8% | +78.2% | −83.0 pts | -1.6% | +21.2% |
| 5 years | -60.9% | +73.2% | −134.1 pts | -17.1% | +11.6% |
| 10 years | -72.5% | +309.6% | −382.1 pts | -12.1% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
24M LCTX shares were sold short on Oct 30, 2026, down 6.1% from the previous report, or 37.66% of the shares available to trade. At recent volumes it would take 19.3 days to buy them back. Over the last 20 sessions, 65.5% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 24,348,055 | -6.1% | 1,263,570 | 19.3 |
| Oct 15, 2026 | 25,927,289 | -10.9% | 1,545,380 | 16.8 |
| Sep 30, 2026 | 29,093,018 | -1.3% | 1,846,827 | 15.8 |
| Sep 15, 2026 | 29,468,651 | +1.7% | 1,106,216 | 26.6 |
| Aug 31, 2026 | 28,983,004 | +2.3% | 876,205 | 33.1 |
| Aug 14, 2026 | 28,331,489 | -4.2% | 808,109 | 35.1 |
| Jul 31, 2026 | 29,561,507 | -1.0% | 1,128,474 | 26.2 |
| Jul 15, 2026 | 29,867,928 | +6.0% | 862,087 | 34.6 |
| Jun 30, 2026 | 28,185,804 | +10.3% | 3,379,386 | 8.3 |
| Jun 15, 2026 | 25,555,170 | -2.0% | 1,109,741 | 23.0 |
| May 29, 2026 | 26,083,430 | +0.6% | 1,045,038 | 25.0 |
| May 15, 2026 | 25,915,824 | +1.3% | 1,546,127 | 16.8 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?